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Abstract
Background: Hepatitis C virus (HCV) is a major causative agent of liver associated diseases throughout the world,
with genotype 3a responsible for most of the cases in Pakistan. Due to the limited efficiency of current therapy,
RNA interference (RNAi) a novel regulatory and powerful silencing approach for molecular therapeutics through a
sequence-specific RNA degradation process represents an alternative option.
Results: The current study was purposed to assess and explore the possibility of RNAi to silence the HCV-3a Core
gene expression, which play complex role in regulation of cell growth and host genes expression essential for
infectivity and disease progression. To identify the potent siRNA target sites, 5 small interfering RNAs (siRNAs)
against Core gene were designed and in vitro transcribed after consensus sequence analysis of different HCV-3a
isolates. Antiviral effects of siRNAs showed upto 80% inhibition of Core gene expression by different siRNAs into
Huh-7 cells as compared with Mock transfected and control siRNAs treated cells. For long lasting effect of siRNAs,
vector based short hairpin siRNAs (shRNAs) were designed and tested against HCV-3a Core which resulted in a
similar pattern of inhibition on RNA and protein expression of HCV Core as synthetic siRNAs. Furthermore, the
efficacy of cell culture tested siRNA and shRNA, were evaluated for inhibition of HCV replication in HCV infected
serum inoculated Huh-7 cells and a significant decrease in HCV viral copy number was observed.
Conclusions: Our results support the possibility of using consensus siRNA and shRNA-based molecular therapy as
a promising strategy in effective inhibition of HCV-3a genotype.
Background
Hepatitis C virus a global public health problem causes
a variety of liver-related diseases varying from an asymp-
tomatic condition to hepatocellular carcinoma (HCC).
More than 3% of the world’s population is chronically
infected with HCV especially in developing countries
including Pakistan where 6% of population is infected
with this viral pathogen [1,2]. The most common HCV
genotype in Pakistan is 3a followed by 3b and 1a with a
strong correlation between chronic HCV infection (gen-
otype 3a) and HCC in Pakistan [3-5]. In most of the
cases HCV escapes immune system while the standard
treatment for HCV, a combination therapy of pegylated
interferon a (PEG-IFN-a) and guanosine analog riba-
virin, has limited efficiency, significant expense, poor
tolerability and assure long term eradication of the virus
in 54-56% treated patients [6-8]. Therefore, development
of molecular approaches like RNA interference, a
sequence specific gene silencing mechanism which has
found to work in mammalian cells, is needed against
HCV. RNAi can be introduced into the cells using two
different approaches: (i) chemically synthesized 21-23nt
small interfering RNAs (ii) a 80-100nt short hairpin
RNA (shRNA) expression cassettes which is then pro-
cessed into active siRNA by the host [9,10]. Both siRNA
and shRNA induce post-transcriptional gene silencing
into mammalian cells in the same manner without acti-
vating an interferon response [11]. Based on these find-
ing a number of investigators have examined antiviral
effects of siRNAs against a number of candidate genes
of different diseases that interfere with replication of
animal viruses.
HCV is highly susceptible to RNAi as replication
occurs in the cytoplasm of liver cells, destruction of
HCV RNA could induce failure of HCV replication.
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replicon systems show that HCV replication is sensitive
to RNAi activity [12-19]. HCV Core located at the
N-terminus of the polyprotein is the viral nucleocapsid
protein that packages the viral RNA in interaction with
t h ee n v e l o p ep r o t e i n s( E 1and E2) [20-22]. Core can be
separated into two domains: an N-terminal two third
hydrophilic domain (D1) and a C-terminal one third
hydrophobic domain (D2) [23]. The D1 domain of Core
protein has RNA-binding and homo-oligomerization
property forming the viral nucleocapsid with numerous
functional activities. The D2 domain is required for
proper folding of domain D1 and membrane character-
istics of the Core [24,25]. Core is a multifunctional pro-
tein influencing a whole array of host cell functions,
including apoptosis, HCV associated-steatosis, immune
cell functions, cell transformation, signal transduction,
and transcriptional regulation leading to HCC [26-32].
A relationship between substitutions in Core region of
HCV-3a with enhanced insulin resistance and oxidative
stress has been observed. Moreover, HCV induced-stea-
t o s i si sm o r ef r e q u e n ta n ds e v e r ei nH C Vg e n o t y p e3
patients due to the presence of specific steatogenic
sequences within this genotype [33-39]. Since Core
plays crucial roles in HCV infection and immunity, it is
helpful to use RNAi against it by targeting virion forma-
tion as new therapeutic option.
In the present study, we aimed to compare the effect
of siRNA and shRNA to specifically target Core gene of
local HCV-3a genotype as new options for developing a
rational antiviral strategy. To avoid potential escape
mutants, as the target sequence we selected HCV Core
gene whose sequence conservation is extremely high
among different HCV genes. It is expected that cleavage
of Core protein mRNA will inhibit nuclear transport
and virus replication. We report here that RNAi tar-
geted against Core effectively inhibited Core gene RNA
and protein expression in a dose dependant manner in
Huh-7 cells irrespective of mode of delivery. The pre-
sent study demonstrates that the RNAi-mediated silen-
c i n go ft h eH C V - 3 aC o r eg e n em a yb eo n eo ft h e
important therapeutic opportunities against HCV-3a
genotype.
Results
Efficient siRNAs targeting HCV-3a Core gene screening
siRNA directed against HCV are expected to success-
fully block replication cycle since HCV being a RNA
virus replicates in the cytoplasm of liver cells without
integration into the host genome. To efficiently silence
Core gene expression by in-vitro transcribed siRNAs
and avoid sequence variants, the most conserved target
sequence were chosen after analyzing a consensus
sequence of local HCV-3a Core sequences and reference
sequences retrieved from GenBank. Negative control
siRNA (scrambled siRNA) with the same nucleotide
composition as the experimental siRNA which lacks sig-
nificant sequence homology to the HCV and human
genome was designed (Table 1). siRNAs were trans-
fected with pCR3.1/FlagTAG/Core vector into Huh-7
cells to investigate their specificity and expression levels
both at mRNA and protein level via semi-quantitative
RT-PCR, Real Time PCR and western blotting. To
assess the effects of chemically synthesized siRNAs on
HCV-3a Core, increasing concentration of siRNAs
(Csi16, Csi27, Csi151, Csi352 and Csi476) were intro-
duced into the cells for 24 and 48hrs. All inhibited HCV
Core RNA in a dose-dependent manner (10, 20 and 40
nM) examined by semi-quantitative RT-PCR. The inhi-
bitory effect of siRNAs Csi16, Csi352 and Csi476 are
stronger even at low concentration, while Csi27 and
Csi151 showed more effect after 24 hrs transfection at
40 nM than at 48 hrs post transfection as compared to
scrambled siRNA (Figure 1A). These results were
further confirmed by Real Time PCR, using primer spe-
cific to HCV Core and GAPDH. Based on the relative
study, the percentages of HCV mRNA in siRNA (40
nM) co-transfected cells over scramble was calculated,
normalizing it with GAPDH. The results of relative
quantitative analysis revealed that the mRNA level of
HCV Core was decreased to 78% in cells treated with
Csi16, 74% with Csi27, 50% with Csi151, 62% with
Csi352 and 84% with Csi476 at 24 hrs post transfection
while 70% Csi16, 58% with Csi27, 38% with Csi151, 61%
with Csi352 and 77% with Csi476 decreased 48 hrs post
transfection. The most effective siRNA reaching a maxi-
mum inhibition of 60-80% after 24 and 48 hrs transfec-
tion were Csi16, Csi27, Csi352 and Csi476 (Figure 1B).
Western blot analysis of protein extracts derived from
the siRNA transfected cells showed that HCV Core pro-
tein expression was reduced in cells co-transfected with
Core specific siRNA, but not in the cells transfected
w i t hs c r a m b l e ds i R N A2 4a n d4 8h r sp o s t - t r a n s f e c t i o n .
Table 1 Sequence of siRNA oligonucleotides directed
against Core gene of HCV 3a genotype
No. siRNA name Sequences 5’-3’
1 Csi16-antisense AAACCTCAAAGAAAAACCAAACCTGTCTC
2 Csi16-sense AATTTGGTTTTTCTTTGAGGTCCTGTCTC
3 Csi27-antisense AAACCAAAAGAAACACCATCCCCTGTCTC
4 Csi27-sense AAGGATGGTGTTTCTTTTGGTCCTGTCTC
5 Csi151-antisense AAAACTTCTGAACGGTCACAGCCTGTCTC
6 Csi151-sense AACTGTGACCGTTCAGAAGTTCCTGTCTC
7 Csi352-antisense AATTTGGGTAAAGTCATCGATCCTGTCTC
8 Csi352-sense AAATCGATGACTTTACCCAAACCTGTCTC
9 Csi476-antisense AAGACGGGATAAATTTCGCAACCTGTCTC
10 Csi476-sense AATTGCGAAATTTATCCCGTCCCTGTCTC
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Page 2 of 11Figure 1 HCV -3a Core specific siRNAs inhibit Core expression. A) Dose dependent silencing effect of synthetic siRNA against Core gene of
HCV-3a. Huh-7 cells were transfected with 0.4 μg of constructed HCV Core vector or Mock along with or without 10, 20 and 40 nM of siRNAs
for 24 and 48 hrs. Cells were harvested and relative RNA determinations were carried out using semi-quantitative RT-PCR. Gene expression
results are given for increasing concentrations of Csi16, Csi27, Csi151, Csi352, and Csi476 siRNAs against HCV-3a Core. Expression levels for Mock-
transfected (M), HCV-3a Core expression plasmid (C), scramble siRNA (Sc), 100 bp DNA Ladder (L) and GAPDH are also shown. B) Quantitative
Real Time PCR analysis of Core 3a or Mock-treated Huh-7 cells along with or without 40 nM of siRNAs for 24 and 48 hrs in comparison to Mock.
Gene expression results from Real Time PCR shows that Csi16, Csi352, and Csi476 siRNAs against HCV-3a Core decrease RNA expression after 24
and 48 hrs transfection. GAPDH was used as internal control. Each independent experiment was performed having triplicate samples. The p
values indicate significant differences between the connected groups. Error bars indicate mean S.D, Csi476 verses other siRNA: p* for 24 and p^
for 48 hrs C). Silencing of HCV-3a Core gene by siRNAs using specific antibodies showed reduction at protein expression level. The protein
expression levels were determined by western blot analysis after 24 and 48 hrs transfection with Mock (M), HCV-3a Core expression plasmid (C)
with and without HCV-3a siRNAs (Csi16, Csi27, Csi151, Csi352, and Csi476) and scramble siRNA (Sc) in Huh-7 cells.
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Page 3 of 11The Csi476 siRNAs was found to be more effective with
upto 70% decreased protein expression after 24 hrs
while all siRNA inhibited protein expression upto 50-
65% after 48 hrs transfection (Figure 1C). These data
s u g g e s tt h a ts y n t h e t i cC o r es i R N An o to n l yh a san e g a -
tive effect on Core mRNA but also it could decrease
viral protein production.
Inhibition of HCV Core expression in HCV serum infected
Huh-7 Cells by siRNA
Since HCV replication in cell culture is limited to
human hepatocytes and their derivatives, now several
reports have verified that HCV can replicate in Huh-7
cells through detection of viral genes as well as viral
copy number by Real Time PCR in both cells and super-
natant [40-43]. The present study was undertaken to
design and test siRNA as an alternative therapy against
HCV, the results indicate that siRNA targeting HCV-3a
Core has the ability to inhibit mRNA and protein in
Huh-7 cells. We speculated that Core siRNAs in Huh-7
cells has the ability to inhibit the replication of HCV.
To test this possibility, Huh-7 serum infected cells were
treated with the Core synthetic siRNAs and subse-
quently incubated for 3 days. Real Time PCR was per-
formed with HCV specific primers (5’UTR) to analyze
the down regulation of RNA by Core specific siRNAs.
Maximal inhibition (70-80%) of HCV transcript levels
was detected on day 3 post-transfection in HCV serum
infected Huh-7 cells. No significant inhibition was
detected in cells transfected with the negative control
siRNA. This result was in accordance with Zekri et al.
2009 [41] who also showed best inhibitory effect of siR-
NAs against 5’UTR on 3
rd day of post-transfection. siR-
NAs against Core gene showed a dramatic reduction in
HCV viral RNA, Csi476 showed a maximum inhibition
of about 89%, while Csi352, Csi16 and Csi27 showed
83%, 68%, and 62% inhibition respectively. Csi151 being
the least effective siRNA showed only 54% inhibition in
viral load (Figure 2). Together, these data suggest a
negative impact of chemically synthesized Core siRNA
on HCV replication that could be used for the down
regulation of Core expression for preventing HCV
pathogenesis.
Targeting HCV Core gene via plasmid-based siRNA
expression system
T h eh a l fl i f eo fs y n t h e t i cs i R N Ad u p l e x e si st o os h o r t
and in some conditions may not stay long enough for
complete elimination of virus in infected cells. Vector
based intracellular delivery of siRNA offers an alterna-
tive strategy which allows continuous production of
siRNA within the cells and permits long-term eradica-
tion of viral gene expression [9]. Therefore, we pro-
posed that plasmid based vector offers an alternative
for intracellular delivery of siRNA for complete inhibition
of viral gene expression and replication. To determine
this possibility, the activity of two siRNA expression
vectors (shRNAs) designed after screening of Core
specific siRNAs, which inhibited Core expression at
least 70%, were determined (Table 2). Two annealed
shRNA oligonucleotides (Csh352 and Csh476) were
cloned into pUbCeGFP vector containing the shRNA
expression cassettes, under the control of UbC promo-
ter. The specific inhibitory effect of shRNA against
HCV-3a Core was determined with and without con-
trol scramble siRNA vector (ScshRNA). Quantitative
Real Time PCR was used to investigate whether intra-
cellular expression of shRNA inhibited HCV Core
RNA expression levels in Huh-7 cells showing 70-75%
with Csh352 and 75-80% with Csh476, while no inhi-
bitory effect was detected in cells transfected with
scramble siRNA even after 72 hrs of transfection. Our
preliminary results have shown that the shRNA inhib-
ited HCV-3a Core RNA expression to almost the same
extent as the synthetic siRNAs (Figure 3A). The speci-
fic inhibitory effects of shRNAs against HCV-3a Core
protein levels were also determined using western
blotting. Both shRNAs effectively inhibited HCV
Core protein expression to 85% (Csh352) and 80%
(Csh476) even after 72 hrs of transfection as compared
to either Mock or scrambled shRNA transfected cells
with no effect on expression levels of GAPDH gene,
suggesting that the suppressive effects of shRNA
against Core were directed specifically to the HCV
gene (Figure 3B).
Inhibition of HCV Core expression in HCV serum infected
Huh-7 cells by shRNA
We speculated that Core specific shRNA in Huh-7 cells
has the ability to inhibit the replication of HCV similar
to chemically synthesized siRNAs. To test this possibility
o fs h R N Ao nH C VR N Ar e p l i c a t i o n ,H u h - 7s e r u m
infected cells were treated with the Core shRNAs and
subsequently incubated for 3 days. Real Time PCR was
performed with HCV specific primers to analyze the
down regulation of viral RNA by Core specific shRNAs
and an approximate 90% decrease in HCV RNA levels
incubated with Csh476 while Csh352 showed 80%
decrease in HCV-serum infected Huh-7 cells. No signifi-
cant inhibition was detected in cells transfected with the
control shRNA (ScshRNA) (Figure 4). Taken together,
these results indicated that in serum-infected Huh-7
cells, direct transfection of shRNAs can specifically pro-
duce RNAi against HCV and reduce HCV viral titer.
Therefore, the use of selective gene silencing like chemi-
cally synthesized and vector based siRNA for the down
regulation of HCV genes might be a target for prevent-
ing HCV induced HCC development.
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HCV is a major cause of chronic hepatitis in Pakistan
with genotype 3a being the most prevalent type [3,4].
Conventional therapies for treating HCV have their lim-
itation and alternative anti-HCV strategies are urgently
needed. As a gene silencing mechanism, RNAi repre-
sents an exciting technology with potential applications
for treatment of viral diseases and investigation of gene
functions. A potential problem that may arise in RNAi
based approach is the error prone nature of HCV gen-
ome with generation of quasispecies during chronic
HCV infection but this problem can be overcome by
designing siRNAs against highly conserved region of
HCV. The region encoding Core is well conserved;
results of nucleotide and deduced amino acid sequence
analysis across diverse strains of HCV reveal 81-88%
nucleotide and 96% amino acid sequence homology
[44,45]. During the course of present study 92% nucleo-
tide sequence homology was observed between different
HCV-3a Core isolates. In the current study, we were
able to show that the introduction of synthetic and vec-
tor based siRNAs into target cells containing HCV Core
caused a dramatic decrease of viral RNA and protein
expression.
HCV infects liver cells, replicates efficiently and con-
tinuously in liver derived Huh-7 cells [46]. Huh-7 cells
Figure 2 Silencing effect of HCV-3a genes-specific siRNAs show a dramatic reduction of viral titer in Huh-7 cells infected with HCV-3a
sera. Huh-7 cells were infected with high titer sera samples from HCV-3a patients (S3a) to establish in vitro cell culture model of HCV-3a, cells
were maintained overnight at 37°C in 5% CO2 for three days. Cells were harvested after siRNA treatment 48 hrs post transfection and
intracellular HCV RNA levels were quantified by Real Time PCR. Data is expressed as mean percent viral load of non-siRNA treated samples. Nine
independent experiments each with triplicate determinations were performed with different sera infected cells. Error bars indicate, mean S.D p <
0.05 verses S3a.
Table 2 Sequence of shRNAs oligonucleotides used in the study
No shRNA name Sequences 5’-3’
1 ScshRNA- sense CTGCTGTTGACAGTGAGCGAAAGTCGAGTCGCGTATGCAGGGTGAAGCCA
CAGATGAACCTGCATACGCGACTCGACCTGCCTACTGCCTCGGACTTCAAGGG
2 ScshRNA- antisense AATTCCCTTGAAGTCCGAGGCAGTAGGCAGGTCGAGTCGCGTATGCAGGTTCAT
CTGTGGCTTCACTGCATACGCGACTCGACTTTCGCTCACTGTCAACAGCAGGTAC
3 Csh352- sense CTGCTGTTGACAGTGAGCGAAAATCGATGACTTTACCCAAAGTGAAGCCACAGAT
GAATTTGGGTAAAGTCATCGATCTGCCTACTGCCTCGGACTTCAAGGG
4 Csh352- antisense AATTCCCTTGAAGTCCGAGGCAGTAGGCAGATCGATGACTTTACCCAAATTCATCT
GTGGCTTCACTGGGTAAAGTCATCGATTTTCGCTCACTGTCAACAGCAGGTAC
5 Csh476-sense CTGCTGTTGACAGTGAGCGAAATTGCGAAATTTATCCCGTCGTGAAGCCACAGATG
AAGACGGGATAAATTTCGCAACTGCCTACTGCCTCGGACTTCAAGGG
6 Csh476-antisense AATTCCCTTGAAGTCCGAGGCAGTAGGCAGTTGCGAAATTTATCCCGTCTTCATCTG
TGGCTTCACCGGGATAAATTTCGCAATTTCGCTCACTGTCAACAGCAGTAC
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Page 5 of 11Figure 3 HCV-3a Core specific shRNAs inhibit mRNA expression. A) Total cellular RNA extracted from transfected Huh-7 after 24, 48 and 72
hrs post-transfection. Gene expression results from Real Time PCR showed that Csh352 and Csh476 shRNAs against HCV-3a Core decrease RNA
expression using gene specific primers in comparison to Mock with GAPDH as internal control. Three independent experiments were performed
having triplicate samples. Error bars indicate mean S.D, *p < 0.01. B) Silencing of HCV-3a Core gene by shRNAs using specific antibodies showed
reduction at protein expression level determined by western blot analysis after 24, 48 and 72 hrs transfection with Mock (M), HCV-3a Core
expression plasmid (C) with and without HCV-3a shRNAs (Csh352 and Csh476) and scramble shRNA (ScshRNA) in Huh-7 cells. Protein levels for
GAPDH gene are also shown as internal control.
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Page 6 of 11are most widely used for liver associated diseases and
fundamental studies for the development of antiviral
agents against HCV as infectious cell culture system
[47-49]. Liu et al. 2006 [14] and Kim et al., 2006 [50],
has designed siRNA against HCV 1b and 1a genome to
explore the silencing of structural genes and showed sig-
nificantly less expression in a dose-dependent manner.
Specificity of binding to the target RNA and functional
importance of the targeted region is essential for effec-
tive gene silencing and successful antiviral activity. As
different domains of Core have different functions,
N-terminal 1-50 amino acid contains RNA and DNA
binding domain, nuclear localization signals (NSL) while
C-terminal 91-191 aa inactivates and binds to Leucine
zipper and 160-194 aa to apolipoprotein II [28,51], siR-
NAs were designed against each domain. Moreover, N-
terminal of Core induces apoptosis and necrosis higher
than those of C-terminal while middle domain with low-
est induced apoptosis and necrosis percentages [52]. The
results in this study demonstrated that siRNAs directed
against domains (N-terminal and C-terminal) of HCV-
3a Core gene resulted in specific inhibition of HCV
RNA synthesis (60-80%), whereas the control siRNA did
not affect HCV and GAPDH mRNA level. To determine
whether the synthesized siRNA could effectively silence
target protein expression, we used Western blotting to
detect the expression of Core protein in transfected
cells. Csi476 was the most effective (upto 70%) siRNA
among all siRNAs which were designed against C and
N-terminal of Core gene making it a potent site for
HCV-3a Core inhibition (Figure 1). Liu et al., 2006 [14]
showed the effect of different siRNAs directed against
HCV 1b Core region (28-509 nt) but the effect of 2 siR-
NAs ranging from 28-200 nt were found to be most
effective upto 70% while the effect of others are stated
as in effective. Contrary to these results, in the present
study, we found C- and N-terminal siRNAs to be all
effective upto 70-80% with Csi151 as least effective. Two
siRNAs against HCV genotype 1b used by Liu et al.
2006 has almost the same sequence as used in the pre-
sent study, Csi27 of our study also showed the same
level of inhibition upto 70% as by CsiRNA 1 used by
Liu et al. The Csi352 also shares sequence homology to
CsiRNA 3 but the difference in siRNA effect cannot be
explain completely as the level of inhibition effect of
CsiRNA 3 is not stated. The difference in siRNAs effect
may be due to base pair differences between genotype
1b and 3a as these differences has also been found to be
involved in several pathogenic disease progressions
[35,36].
Recently different groups have studied the HCV repli-
cation in serum infected liver cell lines which mimics
the naturally occurring HCV virions biology and kinetics
o fH C Vi n f e c t i o ni nh u m a n .W ei n f e c t e dH u h - 7c e l l s
with native viral particles from HCV-3a positive serum
using the same protocol as established [40-43,53]. HCV-
3a Core siRNAs used in the present study was further
screened against HCV serum infected Huh-7 cells. An
exciting finding of this study is decline of HCV viral
titer to a maximum of 90% with gene specific siRNAs.
HCV replication in the Huh-7 cells was observed
through detection of 5’UTR of viral copies by Real Time
PCR in cells 3
rd day post infection. HCV-3a Core siR-
NAs showed a range 54-90% inhibition in viral titer
with Csi476 showing upto 89% and Csi151 only 54%
inhibition (Figure 2). Our data is in agreement with
Z e k r ie ta l . ,2 0 0 9[ 4 1 ] ,w h od e m o n s t r a t e dt h a ts i R N A s
against 5’UTR of HCV genotype-4 inhibited HCV repli-
cation in serum infected Huh-7 cells. Bian et al., 2009
[54] reported that 14 amino acids from the C-terminus
of Core gene are required for proper function of E1 and
at least 12 amino acids from C-terminus of E1 genes are
required for E2 function, influencing the proper glycosy-
lation of E1 and E2 gene. Effect of HCV-3a Core siRNA
on HCV viral titer reduction is possibly due to the inter-
action between different HCV regions and may also due
to the simultaneous degradation of HCV genomic RNA
(as HCV genome contains a positive sense ssRNA).
Treatment of siRNAs revealed significant inhibitory
effects on HCV copy number, indicating that siRNAs
Figure 4 Silencing effect of HCV-3a Core-specific shRNAs show
a dramatic reduction of viral titer in Huh-7 cells infected with
HCV-3a sera. Huh-7 cells were infected with high titer sera samples
from HCV-3a patients to establish in vitro cell culture model of HCV-
3a, cells were maintained overnight at 37°C in 5% CO2, incubation
was continued for 48 hrs. Huh-7 infected cells were again plated
and transfected with shRNAs against HCV-3a genes for additional 48
hrs. Cells were harvested and intracellular HCV RNA levels were
quantified by Real Time PCR. Data are expressed as mean percent
viral load of non-siRNA treated samples. Nine independent
experiments with different sera infected cells and each with
triplicate samples were performed. Error bars indicate, mean S.D p <
0.01 verses S3a.
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Page 7 of 11might be an efficient strategy for molecular HCV
therapeutics.
Various strategies have been adopted in delivery
options of RNA to cells, either directly or through the
introduction of expression vectors in which vector based
strategies are foremost as efficient delivery of siRNA is
major hindrance in effective silencing of HCV replica-
tion. Unexpectedly, siRNAs directed against the 5’UTR
of HCV genotype 1b had less effect on HCV replication
while the coding regions (particularly the highly con-
served protein Core) are more feasible target for RNAi
mediated gene silencing [50]. The expression of shRNAs
targeting specific portions of HCV Core protein expres-
sing in Huh-7 cells was studied showing down regula-
tion of Core protein [55,56]. In both studies shRNAs
directed against C-terminal of Core region showed inhi-
bition of HCV 1b Core upto 70%. Keeping in view these
observations, the expression of shRNAs targeting speci-
fic portions of HCV-3a Core protein is a critical factor
for effective silencing. C-terminal region of Core was
selected for shRNA as biophysical characterization of
the Core protein indicates that residues 125-179 are cri-
tical for the proper folding and oligomerization of the
Core protein [23]. A mammalian expression vector that
directed the synthesis of fully processed siRNAs (Csi352
and Csi476) in HCV-3a Core transfected Huh-7 cells
was used. To confirm the inhibitory effects of shRNA in
the cells, Real Time PCR and Western blotting was per-
formed after 24, 48 and 72 hrs post transfection. These
shRNAs suppressed the expression of Core mRNA
determined by Real Time PCR. This inhibition was not
shRNA side effect as GAPDH mRNA levels were com-
parable both with control and Mock treated cells. Both
siRNA expression plasmids, Csh352 and Csh476, dis-
played potent gene silencing effects (upto 75-80%) on
HCV Core protein expression and viral RNA. Further-
more, transfection of DNA-based vectors expressing siR-
NAs (shRNAs) was as effective as that of synthetic
siRNA in suppressing HCV RNA (Figure 3). In serum
infected Huh-7 cells, shRNA Csh476 was more effective
upto 90% inhibition in HCV viral titer than Csh352
which showed 80% inhibition (Figure 4). Present study
provides experimental evidence that sequence specific
degradation mediated by shRNA expression in the Core
expressing Huh-7 cells down regulates HCV-3a Core
protein expression.
Our results demonstrate that careful and consensus
based sequence selection of targets for siRNA is manda-
tory, not only to achieve maximum effectiveness, but
may also be able to avoid adverse side-effects for thera-
peutic applications. Based on the experiments performed
in this study, it can be concluded that siRNAs directed
against specific domains were more efficient in silencing
viral gene expression. Furthermore, data presented in this
study, also suggest that siRNA targeting HCV-3a Core
can elicit viral RNA from infected cell and potentially
offer an efficient therapeutic option for HCV infection.
These results are in agreement with the previous studies,
suggested that siRNA is the most efficient nucleic acid
based antiviral approach that can be utilized to degrade
HCV genome in the infected cells in a genome sequence
specific manner. In conclusion the efficiency of our
siRNA in inhibiting HCV-3a replication in cells suggests
that RNAi (synthetic or vector based siRNA) may play a
role in clearance of virus during HCV-3a infection.
Methods
Source of samples
The local HCV-3a patient’s serum samples used in this
investigation were obtained from the CAMB (Center for
Applied Molecular Biology) diagnostic laboratory,
Lahore, Pakistan. Serum samples were stored at -80°C
prior to RNA extraction for cloning and viral inocula-
tion experiments. Quantification and genotype was
assessed by CAMB diagnostic laboratory, Lahore,
Pakistan. Patient’s written consent and approval for this
study was obtained from institutional ethics committee.
Plasmid construction
For the construction of expression plasmid, viral RNA
was isolated from 100 μl serum aliquots using Gentra
RNA isolation kit (Gentra System Pennsylvania, USA)
according to the manufacturer’s instructions. 100-200
ng extracted viral RNA was used for RT-PCR using the
SuperScript III one-step RT-PCR system (Invitrogen Life
technologies, USA). HCV complementary DNA (cDNA)
encoding the full length Core protein (amino acid 1-191
of HCV-3a) were amplified employing forward primer
5’GCGATATCATGAGCACACTTCCTAAA’3a n d
reverse primer 5’AATCTAGATCATGGCTGCTGGAT-
GAAT’3. PCR products were cloned into pCR3.1 mam-
malian expression plasmid (kindly provided by Dr. Zafar
Nawaz, University of Miami, USA) with FlagTAG
inserted at the 5’ end of the Core gene with EcoRV and
XbaI restriction sites.
Synthesis of siRNA and shRNA expression vectors
We adopted two methods, siRNA and shRNA mediated
expression, to express RNAi mechanism against Core
region of HCV-3a genome. siRNA oligonucleotides were
designed to the most conserved target regions using the
Ambion’s siRNA design tool http://www.ambion.com/
techlib/misc/siRNA_finder.html. After sequencing
of local HCV-3a patient’s serum samples (GenBank
accession numbers: FJ009580-FJ009586, EU266534-
EU266536) from DNA sequencing facility at CAMB,
Lahore, Pakistan and Full length HCV-3a reference
sequences obtained from GenBank (accession numbers:
Khaliq et al. Virology Journal 2010, 7:318
http://www.virologyj.com/content/7/1/318
Page 8 of 11D17763, AF046866, D28917 and several partial
sequences). These sequences were aligned by using the
free software (CLUSTAL_W option of MEGA v.3.1).
The designed siRNAs (HCV-3a Core and control
Scrambled) were synthesized using Silencer siRNA con-
struction kit according to the manufacturer’s instruction
(Ambion, USA).
To generate gene specific siRNA expression plasmids
(pUbC-shRNAs), two effective siRNA target regions at
3’ end of Core gene were selected. Sense and antisense
strands of shRNA oligonucleotides were chemically
synthesized, annealed at 95°C for 3 min followed by
slow cooling and then cloned into the pUbCeGFP plas-
mid (provided by Dr. Zafar Nawaz, University of Miami,
USA) containing UbC promotor. Scrambled shRNA
(control) cloned into the same vector was used as nega-
tive control in all experiments.
Cell culture and transfection
Huh-7 cell line was kindly provided by Dr. Zafar Nawaz
(University of Miami, USA) and maintained in Dulbec-
co’s modified eagle medium (DMEM) supplemented
with 100 μg/ml penicillin; streptomycin and 10% fetal
bovine serum referred as complete medium (Sigma
Aldrich, USA) at 37°C with 5% CO2. The medium was
renewed every 3rd day and passaged every 4-5 days.
Viable cells were counted using 0.5% trypan blue (Sigma
Aldrich, USA).
The cells were transfected with Core specific (Csi16,
Csi27, Csi151, Csi352, and Csi476) or scrambled siRNAs
along with HCV-3a Core vector (0.4 μgo fc o n s t r u c t e d
vector) to analyze inhibition of HCV-3a Core siRNAs.
Briefly, cells were seeded in 24-well (1 × 10
5/well) or 6-
well (5 × 10
5/well) plates and cultured in complete med-
ium until they became 60-80% confluent. Cells in 24-well
plates were transiently transfected with 10, 20, 40 nM/
well of specific siRNAs or scrambled siRNA (Sc) along
with 0.4 μgo fH C V - 3 aC o r ei ns e r u mf r e em e d i au s i n g
Lipofectamine™ 2000 (Invitrogen Life technologies, CA)
according to the manufacturer’s protocol. After 6 hrs
incubation at 37°C in 5% CO2, complete medium was
added to the cells. Protein analysis was carried out for
above mentioned experiments in 6-well plates with 100
nM/well of each siRNA. Cells were harvested at 24 hrs
post-transfection for gene expression analysis. For asses-
sing the silencing effect of plasmid mediated siRNAs on
HCV-3a Core protein, pUbC-shRNA expression vectors
namely Csh352 and Csh476 were co-transfected (3 μgi n
6-well plate) with HCV-3a Core (1 μg) expression plas-
mids using Lipofectamine™ 2000 as described above.
Isolation of RNA and Gene expression analysis
Total RNA from transfected and non-transfected cells
was isolated using TRIzol reagent (Invitrogen life
technologies, CA), 24 and 48 hrs post-transfection. To
analyze the effect of siRNA and shRNA on Core gene,
cDNA was synthesized with 1 μgo ft o t a lR N A ,u s i n g
Superscript III cDNA synthesis kit (Invitrogen life tech-
nologies, CA) and semi-quantitative RT-PCR was per-
formed using primers of Core gene and GAPDH as
control. Quantitative Real Time PCR was carried out
using Real Time ABI 7500 system (Applied Biosystems
Inc, USA) with SYBR Green mix (Fermentas Interna-
tional Inc, Canada) using gene specific primers: Core 3a
forward primer 5’GGACGACGATGACAAGGACT’3
and Core 3a reverse 5’GGCTGTGACCGTTCAGA-
AGT’3. GAPDH gene was used for normalization as
control using forward primer 5’ACCACAGTCCATGC-
CATCAC’3 and reverse primer 5’TCCACCACCCT-
GTTGCTGTA’3 .T h er e l a t i v eg e n ee x p r e s s i o na n a l y s i s
was carried out by the SDS 3.1 software (Applied
Biosystems Inc, USA). Each individual experiment was
performed in triplicate.
Western blotting
To determine the protein expression levels of HCV
Core, the transfected [with and without HCV-3a siRNAs
(Csi16, Csi27, Csi151, Csi352, and Csi476 and scramble
siRNA) and with and without HCV-3a shRNA trans-
fected cells (Csh352, Csh476 and scramble shRNAs
expression vector)] and non-transfected cells were lysed
with ProteoJET mammalian cell lysis reagent (Fermen-
tas, Canada). Equal amounts of total protein were sub-
jected to electrophoresis on 12% SDS-PAGE and
electrophoretically transferred to a nitrocellulose mem-
brane following the manufacturer’s protocol (Bio-Rad,
CA). After blocking non-specific binding sites with 5%
skimmed milk, blots were incubated with primary
monoclonal antibodies specific to HCV Core and
GAPDH (Santa Cruz Biotechnology Inc, USA) and sec-
ondary Horseradish peroxidase-conjugated anti-goat
anti-mouse antibody (Sigma Aldrich, USA). The protein
expressions were evaluated using chemiluminescence’s
detection kit (Sigma Aldrich, USA).
Viral inoculation and co-transfection with siRNA
Huh-7 cell line was used to establish the in vitro replica-
tion of HCV. A similar protocol was used for viral
inoculation as established by Zekari et al. 2009 [41] and
El-Awardy et al. 2006 [42]. High viral titer > 1 × 10
8
IU/ml from HCV-3a patient’s was used as principle
inoculum in these experiments. Huh-7 cells were main-
tained in 6-well culture plates to semi-confluence,
washed twice with serum-free medium, then inoculated
with 500 μl( 5×1 0
7IU/well) viral load of HCV-3a sera
and 500 μl serum free media. Cells were maintained
o v e r n i g h ta t3 7 ° Ci n5 %C O 2. Next day, adherent cells
were washed three times with 1× PBS, complete
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hrs. Cells were harvested and assessed for viral RNA
quantification by Real Time PCR. To analyze the effect
of siRNA on HCV infection, serum infected Huh-7 cells
were again seeded after three days of infection in 24-
well plates and grown to 80% confluence with 2 ml
medium. The cells were transfected with or without 40
nM/well of Core siRNA/shRNA using Lipofectamine™
2000 (Invitrogen Life technologies, CA) according to the
manufacturer’s protocol. Cells were harvested and intra-
cellular HCV RNA levels were quantified by Real Time
PCR.
Viral load
Cells were harvested for Intracellular viral RNA determi-
nation using Gentra RNA isolation kit (Gentra System
Pennsylvania, USA) according to the manufacturer’s
instructions. For viral quantification Sacace HCV quan-
titative analysis kit (Sacace Biotechnologies Caserta,
Italy) (quantification assay based on the detection of
5’UTR of viral copies) was used by Real Time PCR on
cells 3
rd day post infection. Briefly, 10 μl of extracted
viral RNA was mixed with an internal control derived
from 5’UTR provided by Sacace HCV Real TM Quant
kit and subjected to viral quantification using Real Time
PCR SmartCycler II system (Cepheid Sunnyvale, USA).
Statistical analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
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